Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)

John C. Byrd, Stephen Smith, Nina Wagner-Johnston, Jeff Sharman, Andy I. Chen, Ranjana Advani, Bradley Augustson, Paula Marlton, S. Renee Commerford, Kwame Okrah, Lichuan Liu, Elaine Murray, Elicia Penuel, Ashley F. Ward, Ian W. Flinn

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)'. Together they form a unique fingerprint.

Medicine & Life Sciences